Natera Posts $794M Q3 Revenue, Raises 2026 Outlook

Austin-based Natera, Inc. reported third-quarter revenue of $794.0 million, up 34.1% from $592.2 million a year earlier, and raised its 2026 revenue outlook by $140 million at the midpoint, the company said in a release Thursday that was also furnished to the Securities and Exchange Commission.

Gross margin was 64.7%, compared with 64.9% a year earlier. Net loss narrowed to $59.9 million, or $0.42 a diluted share, from $87.5 million, or $0.64, in the year-ago quarter. StockTitan’s summary of the Form 8-K matched those headline figures.

Test volumes and cash

Natera said it processed about 1,093,100 tests in the quarter, up 22.3% from about 893,600 a year earlier. Oncology tests rose to about 339,500 from about 211,000, a 60.9% increase. Clinical molecular residual disease oncology units grew by 32,700 from the prior quarter.

Loss from operations was $68.3 million, versus $97.6 million a year earlier. Total operating expenses were $576.1 million, up 19.5%. Cash, cash equivalents and restricted cash stood at about $1,097.2 million as of Sept. 30, with outstanding debt of $80.3 million. Cash rose by about $5.7 million from June 30.

Full-year guidance

The company now anticipates 2026 total revenue of $3.005 billion to $3.035 billion, up from a prior range of $2.850 billion to $2.910 billion. It also projected gross margin of about 64% to 66%, selling, general and administrative costs of about $1.225 billion to $1.300 billion, research and development costs of $825 million to $925 million, and positive cash flow for the year.

Sources: Natera, StockTitan (SEC Form 8-K)